

Date: 16/12/2014

Dear Sir/Madam

This is a follow up response relating to Biological treatment.

Please find our response below:

Please see attached spreadsheet on your email for our response.

If you have any queries about this response please contact the information governance manager at foi@homerton.nhs.uk, in the first instance. If, following that, you still have any concerns, you may contact the Information Commissioner either by letter, FOI/EIR Complaints resolution, Wycliffe House, Water Lane, Wilmslow, Cheshire SM9 5AF, or by email www.informationcommissioner.gov.uk to take them further.

Copyright Statement

The material provided is subject to the HUHFT's copyright unless otherwise indicated. Unless expressly indicated on the material to the contrary, it may be reproduced free of charge in any format or medium, provided it is reproduced accurately and not used in a misleading manner. Where any of the copyright items are being re-published or copied to others, you must identify the source of the material and acknowledge the copyright status. Permission to reproduce material does not extend to any material accessed through the Publication Scheme that is the copyright of third parties. You must obtain authorisation to reproduce such material from the copyright holders concerned.

Yours sincerely

Mike Dunne
Information Governance Manager/Deputy Calidcott Guardian

Number of patients currently being treated	TOTAL	Abatacept	Adalimumab	Anakinra	Certolizumab	Etanercept	Golimumab	Infliximab
TOTAL	216	2	86			34	5	70
Total Rheumatology	127	2	56			32	5	16
Rheumatoid Arthritis	73	2	26			17	2	11
Ankylosing Spondylitis	39		19			13	2	5
Psoriatic Arthritis	15		11			2	1	
Psoriasis	13		8			2		
Crohn's disease	64		22					42
Ulcerative Colitis	12							12

Rituximab	Secukinumab	Tocilizumab	Tofacitinib	Ustekinumab	Vedolizumab	Others
7		8		4		
7		8		1		
7		8				
				1		
				3		